Show simple item record

dc.contributor.authorZeeshaan-Ul, H.
dc.contributor.authorAhmed, I.
dc.contributor.authorMatin, R. N.
dc.contributor.authorHomer, V.
dc.contributor.authorLear, J. T.
dc.contributor.authorIsmail, F.
dc.contributor.authorWhitmarsh, T.
dc.contributor.authorGreen, Adèle C
dc.contributor.authorThomson, J.
dc.contributor.authorMilligan, A.
dc.contributor.authorHogan, S.
dc.contributor.authorVan-de-Velde, V.
dc.contributor.authorMitchell-Worsford, L.
dc.contributor.authorKentley, J.
dc.contributor.authorGaunt, C.
dc.contributor.authorJefferson-Hulme, Y.
dc.contributor.authorBowden, S. J.
dc.contributor.authorGaunt, P.
dc.contributor.authorWheatley, K.
dc.contributor.authorProby, C. M.
dc.contributor.authorHarwood, C. A.
dc.date.accessioned2022-08-01T09:07:09Z
dc.date.available2022-08-01T09:07:09Z
dc.date.issued2022en
dc.identifier.citationHasan Z, Ahmed I, Matin RN, Homer V, Lear JT, Ismail F, et al. Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for <scp>SPOT</scp> (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). British Journal of Dermatology. Wiley; 2022.en
dc.identifier.pmid34988975en
dc.identifier.doi10.1111/bjd.20974en
dc.identifier.urihttp://hdl.handle.net/10541/625400
dc.description.abstractBackground: The risk of cutaneous squamous cell carcinoma (cSCC) is significantly increased in organ transplant recipients (OTRs). Clearance of actinic keratoses (AKs) is generally regarded as a surrogate biomarker for cSCC prevention. OTR-cSCC chemoprevention with topical AK treatments has not been investigated in randomized controlled trials (RCTs), although there is evidence that 5% 5-fluorouracil (5-FU) may be chemoprotective in immunocompetent patients. Objectives: To assess the feasibility, activity and evaluation outcomes relevant to the design of a future phase III RCT of topical cSCC chemoprevention in OTRs. Methods: OTRs with 10 or more AKs in predefined areas were randomized 1 : 1 : 1 to topical 5-FU, 5% imiquimod (IMIQ) or sunscreen (sun-protective factor 30+) in a phase II, open-label RCT over 15 months. Feasibility outcomes included proportions of eligible OTRs randomized, completing treatment and willing to be re-treated. AK activity [AK clearance, new AK development, patient-centred outcomes (toxicity, health-related quality of life, HRQoL)] and evaluation methodology (clinical vs. photographic) were assessed. Results: Forty OTRs with 903 AKs were randomized. All feasibility outcomes were met (56% of eligible OTRs were randomized; 89% completed treatment; 81% were willing to be re-treated). AK activity analyses found 5-FU and IMIQ were superior to sunscreen for AK clearance and prevention of new AKs. 5-FU was more effective than IMIQ in AK clearance and prevention in exploratory analyses. Although toxicity was greater with 5-FU, HRQoL outcomes were similar. Conclusions: Trials of topical AK treatments in OTRs for cSCC chemoprevention are feasible and AK activity results support further investigation of 5-FU-based treatments in future phase III trials.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1111/bjd.20974en
dc.titleTopical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)en
dc.typeArticleen
dc.contributor.departmentDepartment of Dermatology, Barts Health NHS Trust, London, UK.en
dc.identifier.journalBritish Journal of Dermatologyen
dc.description.noteen]
refterms.dateFOA2022-08-01T12:56:37Z


Files in this item

Thumbnail
Name:
34988975.pdf
Size:
1.148Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record